Moderate glycation of serum albumin affects folding, stability, and ligand binding

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2105-2116

  Vetter, Stefan W ^a   Indurthi, Venkata S K ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Advanced glycation endproducts; AGE; Diabetes; Non enzymatic glycation; Protein secondary structure; Protein unfolding; Serum albumin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; CARBOXYMETHYL LYSINE; GLUCOSE; GLYOXYLIC ACID; LYSINE; METHYLGLYOXAL; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL CELL; ARTICLE; BETA SHEET; BINDING AFFINITY; BINDING SITE; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; STRUCTURE ANALYSIS; THERMOSTABILITY;

CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; CIRCULAR DICHROISM; GLUCOSE; HUMANS; LIGANDS; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; SERUM ALBUMIN; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 80053652825     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.07.022     Document Type: Article

References (117)

1. Rabbani N., Thornalley P.J. Glycation research in amino acids: a place to call home. Amino Acids 2010, 10.1007/s00726-010-0782-1.
2. Dutta U., Cohenford M.A., Dain J.A. Nonenzymatic glycation of DNA nucleosides with reducing sugars. Anal Biochem 2005, 345(2):171-180.
3. Kislinger T., Schneider M., Pischetsrieder M. Accumulation of non-enzymatic glycation products on proteins and DNA. Res Legal Med 2002, 27:235-247.
4. Miyata T., Kurokawa K., Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000, 11(9):1744-1752.
5. Miyazawa T., Nakagawa K., Shimasaki S., Nagai R. Lipid glycation and protein glycation in diabetes and atherosclerosis. Amino Acids 2010, 10.1007/s00726-010-0772-3.
6. Goodarzi M.T., Navidi A.A., Rezaei M., Babahmadi-Rezaei H. Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes. J Clin Lab Anal 2010, 24(2):72-76.
7. Westwood M.E., Thornalley P.J. Molecular characteristics of methyglyoxal modified bovine and human serum albumins. Comparison with glucose derived advanced glycations end product-modified serum albumins. J Protein Chem 1995, 14(5):359-372.
8. Wautier J.-L., Schmidt Ann M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004, 95(3):233-238.
9. Dills W.L. Protein fructosylation: fructose and the Maillard reaction. Am J Clin Nutr 1993, 58:779(S)-787(S).
10. Frye E.B., Degenhardt T.P., Thorpe S.R., Baynes J.W. Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 1998, 273(30):18714-18719.
11. Munch G., Schicktanz D., Behme A., Gerlach M., Riederer P., Palm D., et al. Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat Biotechnol 1999, 17(10):1006-1010.
12. Davidek T., Blank I. Elucidating the secrets of the Maillard reaction cascade - the role of Amadori compounds. Chimia 2005, 59(11):862.
13. Horvat S., Jakas A. Peptide and amino acid glycation: new insights into the Maillard reaction. J Pept Sci 2004, 10(3):119-137.
14. Pampati P.K., Suravajjala S., Dain J.A. Monitoring nonenzymatic glycation of human immunoglobulin G by methylglyoxal and glyoxal: a spectroscopic study. Anal Biochem 2011, 408(1):59-63.
15. Lo T.W., Westwood M.E., McLellan A.C., Selwood T., Thornalley P.J. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem 1994, 269(51):32299-33205.
16. Gomes R., Sousa Silva M., Quintas A., Cordeiro C., Freire A., Pereira P., et al. Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochem J 2005, 385(Pt 2):339-345.
17. Hudson B.I., Hofmann M.A., Bucciarelli L., Wendt T., Moser B., Lu Y., et al. Glycation and diabetes: the RAGE connection. Curr Sci 2002, 83(12):1515-1521.
18. Goldstein D.E., Little R.R., Lorenz R.A., Malone J.I., Nathan D., Peterson C.M., et al. Tests of glycemia in diabetes. Diabetes Care 2004, 27(7):1761-1773.
19. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995, 44(8):968-983. listed Na.
20. Hudson B.I., Schmidt A.M. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res 2004, 21(7):1079-1086.
21. Rong L.L., Gooch C., Szabolcs M., Herold K.C., Lalla E., Hays A.P., et al. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor Neurol Neurosci 2005, 23(5,6):355-365.
22. Barile G.R., Schmidt A.M. RAGE and its ligands in retinal disease. Curr Mol Med 2007, 7(8):758-765.
23. Dhar A., Desai K., Liu J., Wu L. Methylglyoxal, protein binding and biological samples: are we getting the true measure?. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(11-12):1093-1100.
24. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999, 344(Pt 1):109-116.
25. Westwood M.E., Thornalley P.J. Induction of synthesis and secretion of interleukin 1 beta in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts. Immunol Lett 1996, 50(1-2):17-21.
26. Turk Z., Nemet I., Varga-Defteardarovic L., Car N. Elevated level of methylglyoxal during diabetic ketoacidosis and its recovery phase. Diabetes Metab 2006, 32(2):176-180.
27. Ohgami N., Nagai R., Ikemoto M., Arai H., Kuniyasu A., Horiuchi S., et al. CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 2001, 276(5):3195-3202.
28. Ohgami N., Nagai R., Ikemoto M., Arai H., Miyazaki A., Hakamata H., et al. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications 2002, 16(1):56-59.
29. Sourris K.C., Forbes J.M. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets. Curr Drug Targets 2009, 10(1):42-50.
30. Horiuchi S., Sakamoto Y., Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003, 25(3-4):283-292.
31. Prevo R., Banerji S., Ni J., Jackson D.G. Rapid plasma membrane-endosomal trafficking of the lymph node sinus and high endothelial venule scavenger receptor/homing receptor stabilin-1 (FEEL-1/CLEVER-1). J Biol Chem 2004, 279(50):52580-52592.
32. Tamura Y., Adachi H., Osuga J., Ohashi K., Yahagi N., Sekiya M., et al. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 2003, 278(15):12613-12617.
33. Miyazaki A., Nakayama H., Horiuchi S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 2002, 12(6):258-262.
34. Marsche G., Weigle B., Sattler W., Malle E. Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein. FASEB J 2007, 21(12):3075-3082.
35. Greaves D.R., Gordon S. The macrophage scavenger receptor at 30years of age: current knowledge and future challenges. J Lipid Res 2009, 50:S282-S286. Suppl.
36. Araki N., Higashi T., Mori T., Shibayama R., Kawabe Y., Kodama T., et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995, 230(2):408-415.
37. Li Y.M., Mitsuhashi T., Wojciechowicz D., Shimizu N., Li J., Stitt A., et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A 1996, 93(20):11047-11052.
38. Stitt A.W., Burke G.A., Chen F., McMullen C.B., Vlassara H. Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. FASEB J 2000, 14(15):2390-2392.
39. Stitt A.W., McGoldrick C., Rice-McCaldin A., McCance D.R., Glenn J.V., Hsu D.K., et al. Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 2005, 54(3):785-794.
40. Vlassara H., Li Y.M., Imani F., Wojciechowicz D., Yang Z., Liu F.T., et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995, 1(6):634-646.
41. Miyata T., Hori O., Zhang J., Yan S.D., Ferran L., Iida Y., et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta-2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Investig 1996, 98(5):1088-1094.
42. Schmidt A.M., Hori O., Cao R., Yan S.D., Brett J., Wautier J.L., et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996, 45(Suppl. 3):S77-S80.
43. Ramasamy R., Yan S.F., Schmidt A.M. Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res 2007, 51(9):1111-1115.
44. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005, 83(11):876-886.
45. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Du Yan S., et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999, 274(44):31740-31749.
46. Buetler T.M., Leclerc E., Baumeyer A., Latado H., Newell J., Adolfsson O., et al. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 2008, 52(3):370-378.
47. Pertynska-Marczewska M., Kiriakidis S., Wait R., Beech J., Feldmann M., Paleolog E.M. Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. Cytokine 2004, 28(1):35-47.
48. Stitt A.W., He C., Vlassara H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 1999, 256(3):549-556.
49. Valencia J.V., Weldon S.C., Quinn D., Kiers G.H., DeGroot J., TeKoppele J.M., et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 2004, 324(1):68-78.
50. Yang C.W., Vlassara H., Peten E.P., He C.J., Striker G.E., Striker L.J. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 1994, 91(20):9436-9440.
51. Matsumoto S., Yoshida T., Murata H., Harada S., Fujita N., Nakamura S., et al. Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry 2008, 47(47):12299-12311.
52. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Agalou S., Babaei-Jadidi R., et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003, 375(Pt 3):581-592.
53. Teerlink T., Barto R., Ten Brink H.J., Schalkwijk C.G. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004, 50(7):1222-1228.
54. Lieuw A.F.M.L., van Hinsbergh V.W., Teerlink T., Barto R., Twisk J., Stehouwer C.D., et al. Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Nephrol Dial Transplant 2004, 19(3):631-636.
55. Ikeda K., Nagai R., Sakamoto T., Sano H., Araki T., Sakata N., et al. Immunochemical approaches to AGE-structures: characterization of anti-AGE antibodies. J Immunol Methods 1998, 215(1-2):95-104.
56. Dukic-Stefanovic S., Schicktanz D., Wong A., Palm D., Riederer P., Niwa T., et al. Characterization of antibody affinities using an AGE-modified dipeptide spot library. J Immunol Methods 2002, 266(1-2):45-52.
57. Schmitt A., Schmitt J., Munch G., Gasic-Milencovic J. Characterization of advanced glycation end products for biochemical studies: side chain modifications and fluorescence characteristics. Anal Biochem 2005, 338(2):201-215.
58. Schmitt A., Gasic-Milenkovic J., Schmitt J. Characterization of advanced glycation end products: mass changes in correlation to side chain modifications. Anal Biochem 2005, 346(1):101-106.
59. Hegele J., Buetler T., Delatour T. Comparative LC-MS/MS profiling of free and protein-bound early and advanced glycation-induced lysine modifications in dairy products. Anal Chim Acta 2008, 617(1-2):85-96.
60. Joseph K.S., Anguizola J., Hage D.S. Binding of tolbutamide to glycated human serum albumin. J Pharm Biomed Anal 2011, 54(2):426-432.
61. Joseph K.S., Anguizola J., Jackson A.J., Hage D.S. Chromatographic analysis of acetohexamide binding to glycated human serum albumin. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878(28):2775-2781.
62. Joseph K.S., Hage D.S. The effects of glycation on the binding of human serum albumin to warfarin and L-tryptophan. J Pharm Biomed Anal 2010, 53(3):811-818.
63. Rondeau P., Navarra G., Cacciabaudo F., Leone M., Bourdon E., Militello V. Thermal aggregation of glycated bovine serum albumin. Biochim Biophys Acta 2010, 1804(4):789-798.
64. Bouma B., Kroon-Batenburg L.M., Wu Y.P., Brunjes B., Posthuma G., Kranenburg O., et al. Glycation induces formation of amyloid cross-beta structure in albumin. J Biol Chem 2003, 278(43):41810-41819.
65. Nagai R., Mera K., Nakajou K., Fujiwara Y., Iwao Y., Imai H., et al. The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs. Biochim Biophys Acta 2007, 1772(11-12):1192-1198.
66. Valencia J.V., Mone M., Koehne C., Rediske J., Hughes T.E. Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products (AGEs). Diabetologia 2004, 47(5):844-852.
67. Thornalley P.J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-Grand) 1998, 44(7):1013-1023.
68. Bennhold H., Kallee E. Comparative studies on the half-life of I 131-labeled albumins and nonradioactive human serum albumin in a case of analbuminemia. J Clin Invest 1959, 38(5):863-872.
69. Schmitt A., Meiners I., Schmitt J., Noeller J., Ihling C., Muench G., et al. Two analytical methods to study the interaction of AGEs with cell surface proteins. J Biochem Biophys Methods 2005, 65(2-3):121-136.
70. Ahmed N., Argirov O.K., Minhas H.S., Cordeiro C.A., Thornalley P.J. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem J 2002, 364(Pt 1):1-14.
71. Fields R., Dixon H.B. Micro method for determination of reactive carbonyl groups in proteins and peptides, using 2,4-dinitrophenylhydrazine. Biochem J 1971, 121(4):587-589.
72. Reznick A.Z., Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994, 233:357-363.
73. Udenfriend S., Stein S., Bohlen P., Dairman W., Weigele M. Fluorescamin: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 1972, 178:871-872.
74. Lorenzen A., Kennedy S.W. A fluorescence-based protein assay for use with a microplate reader. Anal Biochem 1993, 214(1):346-348.
75. Smith R.E., MacQuarrie R. A sensitive fluorometric method for the determination of arginine using 9,10-phenanthrenequinone. Anal Biochem 1978, 90(1):246-255.
76. Itano H.A., Yamada S. 2-Aminophenanthroimidazole, fluorescent product of the reaction of phenanthrenequinone with arginine. Anal Biochem 1972, 48(2):483-490.
77. Sreerama N., Venyaminov S.Y., Woody R.W. Analysis of protein circular dichroism spectra based on the tertiary structure classification. Anal Biochem 2001, 299(2):271-274.
78. Cardamone M., Puri N.K. Spectrofluorimetric assessment of the surface hydrophobicity of proteins. Biochem J 1992, 282(Pt 2):589-593.
79. MacCarthy P. Simplified experimental route for obtaining Job's curves. Anal Chem 1978, 50(14):2165.
80. Birdsall B., King R.W., Wheeler M.R., Lewis C.A., Goode S.R., Dunlap R.B., et al. Correction for light absorption in fluorescence studies of protein-ligand interactions. Anal Biochem 1983, 132(2):353-361.
81. Degenhardt T.P., Thorpe S.R., Baynes J.W. Chemical modification of proteins by methylglyoxal. Cell Mol Biol (Noisy-le-Grand) 1998, 44(7):1139-1145.
82. Oya T., Hattori N., Mizuno Y., Miyata S., Maeda S., Osawa T., et al. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 1999, 274(26):18492-18502.
83. Kessel L., Kalinin S., Nagaraj R.H., Larsen M., Johansson L.B. Time-resolved and steady-state fluorescence spectroscopic studies of the human lens with comparison to argpyrimidine, pentosidine and 3-OH-kynurenine. Photochem Photobiol 2002, 76(5):549-554.
84. Coussons P.J., Jacoby J., McKay A., Kelly S.M., Price N.C., Hunt J.V. Glucose modification of human serum albumin: a structural study. Free Radic Biol Med 1997, 22(7):1217-1227.
85. Fujimori E. Cross-linking and fluorescence changes of collagen by glycation and oxidation. Biochim Biophys Acta 1989, 998(2):105-110.
86. Tan A.L., Sourris K.C., Harcourt B.E., Thallas-Bonke V., Penfold S., Andrikopoulos S., et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2010, 298(3):F763-F770.
87. Coughlan M.T., Thorburn D.R., Penfold S.A., Laskowski A., Harcourt B.E., Sourris K.C., et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009, 20(4):742-752.
88. Thornalley P.J., Argirova M., Ahmed N., Mann V.M., Argirov O., Dawnay A. Mass spectrometric monitoring of albumin in uremia. Kidney Int 2000, 58(5):2228-2234.
89. Ahmed N., Thornalley P.J. Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Ann N Y Acad Sci 2005, 1043:260-266.
90. Youssef D., El Abbassi A., Jordan R.M., Peiris A.N. Fructosamine - an underutilized tool in diabetes management: case report and literature review. Tenn Med 2008, 101(11):31-33.
91. Wahid S.T., Sultan J., Handley G., Saeed B.O., Weaver J.U., Robinson A.C. Serum fructosamine as a marker of 5-year risk of developing diabetes mellitus in patients exhibiting stress hyperglycaemia. Diabet Med 2002, 19(7):543-548.
92. Odetti P., Garibaldi S., Noberasco G., Aragno I., Valentini S., Traverso N., et al. Levels of carbonyl groups in plasma proteins of type 2 diabetes mellitus subjects. Acta Diabetol 1999, 36(4):179-183.
93. Turk Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol Res 2010, 59(2):147-156.
94. Sarkar P., Kar K., Mondal M.C., Chakraborty I., Kar M. Elevated level of carbonyl compounds correlates with insulin resistance in type 2 diabetes. Ann Acad Med Singapore 2010, 39(12):909-914.
95. Viswanathan V., Beardsley A.L., Walvoord E.C., Nebesio T.D. Extreme hyperglycemia and hyperosmolar state in new onset type 1 diabetes: are sugar- and salt-containing beverages at fault?. Clin Pediatr (Phila) 2011, 50(4):360-363.
96. Gupta A., Rohrscheib M., Tzamaloukas A.H. Extreme hyperglycemia with ketoacidosis and hyperkalemia in a patient on chronic hemodialysis. Hemodial Int 2008, 12(Suppl 2):S43-S47.
97. Al-Kudsi R.R., Daugirdas J.T., Ing T.S., Kheirbek A.O., Popli S., Hano J.E., et al. Extreme hyperglycemia in dialysis patients. Clin Nephrol 1982, 17(5):228-231.
98. Kisugi R., Kouzuma T., Yamamoto T., Akizuki S., Miyamoto H., Someya Y., et al. Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin Chim Acta 2007, 382(1-2):59-64.
99. Chaplen F.W., Fahl W.E., Cameron D.C. Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. Proc Natl Acad Sci U S A 1998, 95(10):5533-5538.
100. Takeda K., Wada A., Yamamoto K., Moriyama Y., Aoki K. Conformational change of bovine serum albumin by heat treatment. J Protein Chem 1989, 8(5):653-659.
101. Barnaby O.S., Cerny R.L., Clarke W., Hage D.S. Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin Chim Acta 2011, 412(3-4):277-285.
102. Barnaby O.S., Wa C., Cerny R.L., Clarke W., Hage D.S. Quantitative analysis of glycation sites on human serum albumin using (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta 2010, 411(15-16):1102-1110.
103. Barnaby O.S., Cerny R.L., Clarke W., Hage D.S. Quantitative analysis of glycation patterns in human serum albumin using (16)O/(18)O-labeling and MALDI-TOF MS. Clin Chim Acta 2011, 412(17-18):1606-1615.
104. Wa C., Cerny R.L., Clarke W.A., Hage D.S. Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta 2007, 385(1-2):48-60.
105. Povey J.F., Howard M.J., Williamson R.A., Smales C.M. The effect of peptide glycation on local secondary structure. J Struct Biol 2008, 161(2):151-161.
106. Murayama K., Tomida M. Heat-induced secondary structure and conformation change of bovine serum albumin investigated by Fourier transform infrared spectroscopy. Biochemistry 2004, 43(36):11526-11532.
107. Mendez D.L., Jensen R.A., McElroy L.A., Pena J.M., Esquerra R.M. The effect of non-enzymatic glycation on the unfolding of human serum albumin. Arch Biochem Biophys 2005, 444(2):92-99.
108. Pico G.A. Thermodynamic features of the thermal unfolding of human serum albumin. Int J Biol Macromol 1997, 20(1):63-73.
109. Farruggia B., Rodriguez F., Rigatuso R., Fidelio G., Pico G. The participation of human serum albumin domains in chemical and thermal unfolding. J Protein Chem 2001, 20(1):81-89.
110. Michnik A. Thermal stability of bovine serum albumin DSC study. J Therm Anal Calori 2003, 71:509-519.
111. Daniel E., Weber G. Cooperative effects in binding by bovine serum albumin. I. The binding of 1-anilino-8-naphthalenesulfonate. Fluorimetric titrations. Biochemistry 1966, 5(6):1893-1900.
112. Naik D.V., Jewell C.F., Schulman S.G. Binding of cupric ions to bovine serum albumin. J Pharm Sci 1975, 64(7):1243-1245.
113. Togashi D.M., Ryder A.G. A fluorescence analysis of ANS bound to bovine serum albumin: binding properties revisited by using energy transfer. J Fluoresc 2008, 18(2):519-526.
114. Barzegar A., Moosavi-Movahedi A.A., Sattarahmady N., Hosseinpour-Faizi M.A., Aminbakhsh M., Ahmad F., et al. Spectroscopic studies of the effects of glycation of human serum albumin on L-Trp binding. Protein Pept Lett 2007, 14(1):13-18.
115. Okabe N., Hashizume N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull 1994, 17(1):16-21.
116. Mera K., Takeo K., Izumi M., Maruyama T., Nagai R., Otagiri M. Effect of reactive-aldehydes on the modification and dysfunction of human serum albumin. J Pharm Sci 2010, 99(3):1614-1625.
117. Joseph K.S., Hage D.S. Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878(19):1590-1598.